cisapride has been researched along with Arrhythmias, Cardiac in 70 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study prospectively the effects of cisapride on ventricular repolarization, depolarization, and arrhythmia markers in neonates, we determined before and three days after starting cisapride (1 mg/kg/day): corrected QT interval (QTc) and QT dispersion (QTd) on standard ECGs, and duration of filtered QRS (fQRS) and of low amplitude (<40 microV) terminal signals (LAS40, ms) and root mean square of the last 40 ms (RMS40, microV) using high-gain signal-averaged ECG (SAECG)." | 9.09 | Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants. ( Belli, DC; Ferrazzini, G; Friedli, B; Zamora, SA, 2001) |
| "Cisapride is a propulsive agent, withdrawn from most of the world's health institutes because of its recorded fatalities in addition to serious side effects such as severe arrhythmias." | 8.87 | Cisapride for intestinal constipation. ( Aboumarzouk, OM; Agarwal, T; Antakia, R; Nelson, RL; Shariff, U, 2011) |
| "Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride." | 8.81 | Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. ( Barbey, JT; Lazzara, R; Zipes, DP, 2002) |
| "We aimed to examine the association between cisapride and ventricular arrhythmia, and examine the relationship to dose and CYP3A4 inhibitors." | 7.74 | Cisapride and ventricular arrhythmia. ( Bilker, WB; Hennessy, S; Kimmel, SE; Leonard, CE; Newcomb, C, 2008) |
| "To evaluate the risk of serious ventricular arrhythmia (SVA) with cisapride use in the United States." | 7.71 | Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. ( Cali, C; Enger, C; Walker, AM, 2002) |
| "While cisapride was being marketed from 1993-1999, the FDA received reports of the following patients: 117 who developed QT prolongation; 107, torsades de pointes; 16, polymorphic ventricular tachycardia; 18, ventricular fibrillation; 27, ventricular tachycardia; 25, cardiac arrest; 16, serious (unspecified) arrhythmia; and 15, sudden death; for a total of 341 individual patients affected, following use of cisapride." | 7.71 | Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. ( Corken, A; Gallo-Torres, H; Rodriguez, EM; Talarico, L; Wysowski, DK, 2001) |
| "Arrhythmic events (sudden deaths and other events compatible with serious ventricular arrhythmias) were sought among 36,743 patients prescribed cisapride in the United Kingdom and Saskatchewan, Canada." | 7.70 | The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. ( Dicker, LW; Dreyer, NA; Lanza, LL; Loughlin, JE; Szneke, P; Walker, AM; Weatherby, LB; Yee, CL, 1999) |
| "Cisapride is a gastrointestinal prokinetic agent that is used worldwide in the treatment of gastrointestinal motility-related disorders in premature infants, full-term infants, and children." | 6.40 | The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition. ( Belli, DC; Benatar, A; Cadranel, S; Cucchiara, S; Dupont, C; Gottrand, F; Hassall, E; Heymans, HS; Kearns, G; Kneepkens, CM; Koletzko, S; Milla, P; Polanco, I; Staiano, AM; Vandenplas, Y, 1999) |
| " Of these, 134 were on cisapride therapy for suspected gastroesophageal reflux and 118 were not on cisapride and served as controls." | 5.09 | Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. ( Benatar, A; Decraene, T; Feenstra, A; Vandenplas, Y, 2000) |
| "To study prospectively the effects of cisapride on ventricular repolarization, depolarization, and arrhythmia markers in neonates, we determined before and three days after starting cisapride (1 mg/kg/day): corrected QT interval (QTc) and QT dispersion (QTd) on standard ECGs, and duration of filtered QRS (fQRS) and of low amplitude (<40 microV) terminal signals (LAS40, ms) and root mean square of the last 40 ms (RMS40, microV) using high-gain signal-averaged ECG (SAECG)." | 5.09 | Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants. ( Belli, DC; Ferrazzini, G; Friedli, B; Zamora, SA, 2001) |
| "Cisapride is a propulsive agent, withdrawn from most of the world's health institutes because of its recorded fatalities in addition to serious side effects such as severe arrhythmias." | 4.87 | Cisapride for intestinal constipation. ( Aboumarzouk, OM; Agarwal, T; Antakia, R; Nelson, RL; Shariff, U, 2011) |
| "Although the new second-generation nonsedative antihistamines terfenadine and astemizole were launched as highly selective and specific H(1)-receptor antagonists, they were later found to cause prolongation of the QT-interval and severe cardiac arrhythmias." | 4.81 | Cardiotoxicity of new antihistamines and cisapride. ( Paakkari, I, 2002) |
| "Adverse cardiac events, typically long QT syndrome, have been reported in patients treated with the gastrointestinal prokinetic agent cisapride." | 4.81 | Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. ( Barbey, JT; Lazzara, R; Zipes, DP, 2002) |
| "The withdrawal of cisapride from the market will present challenges for physicians treating patients with nocturnal heartburn, gastroparesis, and dyspepsia." | 4.80 | Cisapride: limited access and alternatives. ( Richter, JE, 2000) |
| "Significant AP prolongation (a pro-arrhythmia marker) was seen in response to quinidine and quinine." | 4.12 | An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms. ( Christini, DJ; Clark, AP; Kalola, D; Krogh-Madsen, T; Wei, S, 2022) |
| "Amiodarone and cisapride are both known to prolong the QT interval, yet the two drugs have different effects on arrhythmia." | 3.78 | Impact of amiodarone and cisapride on simulated human ventricular electrophysiology and electrocardiograms. ( Dössel, O; Rombach, C; Scholz, EP; Seemann, G; Wilhelms, M, 2012) |
| "We aimed to examine the association between cisapride and ventricular arrhythmia, and examine the relationship to dose and CYP3A4 inhibitors." | 3.74 | Cisapride and ventricular arrhythmia. ( Bilker, WB; Hennessy, S; Kimmel, SE; Leonard, CE; Newcomb, C, 2008) |
| "To evaluate the risk of serious ventricular arrhythmia (SVA) with cisapride use in the United States." | 3.71 | Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. ( Cali, C; Enger, C; Walker, AM, 2002) |
| "While cisapride was being marketed from 1993-1999, the FDA received reports of the following patients: 117 who developed QT prolongation; 107, torsades de pointes; 16, polymorphic ventricular tachycardia; 18, ventricular fibrillation; 27, ventricular tachycardia; 25, cardiac arrest; 16, serious (unspecified) arrhythmia; and 15, sudden death; for a total of 341 individual patients affected, following use of cisapride." | 3.71 | Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. ( Corken, A; Gallo-Torres, H; Rodriguez, EM; Talarico, L; Wysowski, DK, 2001) |
| "Arrhythmic events (sudden deaths and other events compatible with serious ventricular arrhythmias) were sought among 36,743 patients prescribed cisapride in the United Kingdom and Saskatchewan, Canada." | 3.70 | The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. ( Dicker, LW; Dreyer, NA; Lanza, LL; Loughlin, JE; Szneke, P; Walker, AM; Weatherby, LB; Yee, CL, 1999) |
| "Several cases of QT prolongation and ventricular tachyarrhythmia have been reported with domperidone, a gastrokinetic and antiemetic agent available worldwide but still under investigation in the United States." | 3.70 | Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. ( Cardinal, R; Daleau, P; Drolet, B; Rousseau, G; Turgeon, J, 2000) |
| "Life-threatening arrhythmias and prolonged QT interval have been reported in adults and children using cisapride, a medication structurally similar to procainamide." | 3.70 | QT interval in children and infants receiving cisapride. ( Dinari, G; Fogelman, R; Levine, A; Shamir, R; Sirota, L; Zangen, Z, 1998) |
| "The effects of cisapride on the gastrointestinal contractile activity and pharmacokinetics of disopyramide were determined in beagle dogs and patients with arrhythmia." | 3.68 | Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide. ( Akima, M; Azumi, T; Fukuzaki, H; Inatome, T; Kuroda, T; Nakamura, H; Takanashi, H; Yogo, K; Yoshihara, Y, 1992) |
| " Instead, single dosing on specific days is proposed to be a better way to characterize the teratogenic potential of Ikr blocking drugs." | 2.44 | Embryonic cardiac arrhythmia and generation of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs. ( Danielsson, BR; Danielsson, C; Nilsson, MF, 2007) |
| "Cisapride is a gastrointestinal prokinetic agent that is used worldwide in the treatment of gastrointestinal motility-related disorders in premature infants, full-term infants, and children." | 2.40 | The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition. ( Belli, DC; Benatar, A; Cadranel, S; Cucchiara, S; Dupont, C; Gottrand, F; Hassall, E; Heymans, HS; Kearns, G; Kneepkens, CM; Koletzko, S; Milla, P; Polanco, I; Staiano, AM; Vandenplas, Y, 1999) |
| "Drugs can cause cardiac arrhythmias in a number of clinical situations, and many of the implicated agents are used to treat non-cardiac conditions." | 2.40 | Drug-induced cardiac arrhythmias: incidence, prevention and management. ( Doig, JC, 1997) |
| " In responses to all three QT-lengthening compounds, RR, QT and QTc(F) lengthened similarly in a dose-response manner in both the failing and normal hearts." | 1.38 | Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts. ( Hamlin, RL; Kijtawornrat, A; Sawangkoon, S, 2012) |
| "This suggests a lower clinical risk of cardiac arrhythmia in CJ-033466 compared with the other 2 agonists." | 1.34 | The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. ( Kawatsu, R; Kohmura, Y; Toga, T, 2007) |
| "We studied subjects with gastroesophageal reflux disease (apparent life-threatening events, apneas, bradycardias) before and 3 days after starting cisapride (0." | 1.32 | 24-hour electrocardiogram before and during cisapride treatment in neonates and infants. ( Belli, DC; Friedli, B; Jaeggi, E; Zamora, SA, 2004) |
| "Torsade de pointes is a rare but potentially fatal ventricular arrhythmia associated with drug-induced delayed repolarization and prolongation of the QT interval." | 1.31 | The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. ( Cox, BF; Gintant, GA; Limberis, JT; McDermott, JS; Wegner, CD, 2001) |
| "Cisapride, which has recently been withdrawn by the Food and Drug Administration and is no longer an approved therapy, was commonly used for preterm infant care to improve the advance of enteral feedings and to reduce reflux and associated apnea." | 1.31 | Cisapride associated with QTc prolongation in very low birth weight preterm infants. ( Ariagno, R; Dubin, A; Kikkert, M; Mirmiran, M, 2001) |
| "(2) Cases of cardiac arrhythmia and death have occurred, even in the absence of underlying factors such as high doses and interactions with enzyme-inhibiting drugs (especially macrolide antibiotics, HIV protease inhibitors and antifungal imidazoles)." | 1.31 | Severe cardiac arrythmia on cisapride. ( , 2000) |
| "Renzapride was slightly more potent than prucalopride (IC(50) = 1." | 1.31 | Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. ( Baró, I; Bouyssou, T; Escande, D; Potet, F, 2001) |
| "Ventricular arrhythmias have been associated with both cisapride and hemodialysis (HD)." | 1.31 | Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ( Barone, JA; Costeas, C; Mathis, AS, 2001) |
| "One patient died from ventricular arrhythmia 12 days after discontinuing cisapride." | 1.31 | Retrospective analysis of cisapride-induced QT changes in end-stage renal disease patients. ( Gunderson, BW; Hentges, MJ; Lewis, MJ, 2000) |
| "Cisapride (Propulsid) is a gastrointestinal prokinetic agent commonly used to treat nocturnal heartburn as well as a variety of other gastrointestinal disorders." | 1.30 | A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. ( Brown, AM; Dennis, A; Rampe, D; Roy, ML, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (25.71) | 18.2507 |
| 2000's | 41 (58.57) | 29.6817 |
| 2010's | 9 (12.86) | 24.3611 |
| 2020's | 2 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Rampe, D | 1 |
| Roy, ML | 1 |
| Dennis, A | 1 |
| Brown, AM | 2 |
| Jia, L | 1 |
| Sun, H | 1 |
| Clark, AP | 1 |
| Wei, S | 1 |
| Kalola, D | 1 |
| Krogh-Madsen, T | 1 |
| Christini, DJ | 1 |
| Hamatani, T | 1 |
| Noda, N | 1 |
| Takagaki, T | 1 |
| Yodo, Y | 1 |
| Kawai, H | 1 |
| Kakuyama, H | 1 |
| Kaji, Y | 1 |
| Fujio, Y | 1 |
| Keller, N | 1 |
| Dhein, S | 1 |
| Neumann, J | 1 |
| Gergs, U | 1 |
| Caraballo, L | 1 |
| Molina, G | 1 |
| Weitz, D | 1 |
| Piskulic, L | 1 |
| Avila, A | 1 |
| Marzi, M | 1 |
| Windley, MJ | 1 |
| Mann, SA | 1 |
| Vandenberg, JI | 1 |
| Hill, AP | 1 |
| Chen, Z | 1 |
| Xian, W | 1 |
| Bellin, M | 1 |
| Dorn, T | 1 |
| Tian, Q | 1 |
| Goedel, A | 1 |
| Dreizehnter, L | 1 |
| Schneider, CM | 1 |
| Ward-van Oostwaard, D | 1 |
| Ng, JK | 1 |
| Hinkel, R | 1 |
| Pane, LS | 1 |
| Mummery, CL | 1 |
| Lipp, P | 1 |
| Moretti, A | 1 |
| Laugwitz, KL | 1 |
| Sinnecker, D | 1 |
| Hennessy, S | 2 |
| Leonard, CE | 2 |
| Palumbo, CM | 1 |
| Bilker, WB | 2 |
| Newcomb, C | 2 |
| Kimmel, SE | 2 |
| Mearín, F | 1 |
| Plazas, MJ | 1 |
| Mas, M | 1 |
| Heras, J | 1 |
| Aboumarzouk, OM | 1 |
| Agarwal, T | 1 |
| Antakia, R | 1 |
| Shariff, U | 1 |
| Nelson, RL | 1 |
| Jonsson, MK | 1 |
| Vos, MA | 1 |
| Mirams, GR | 1 |
| Duker, G | 2 |
| Sartipy, P | 1 |
| de Boer, TP | 1 |
| van Veen, TA | 1 |
| Kijtawornrat, A | 2 |
| Sawangkoon, S | 1 |
| Hamlin, RL | 2 |
| Wilhelms, M | 1 |
| Rombach, C | 1 |
| Scholz, EP | 1 |
| Dössel, O | 1 |
| Seemann, G | 1 |
| Enger, C | 1 |
| Cali, C | 1 |
| Walker, AM | 2 |
| Keene, BW | 1 |
| Hamlin, DM | 1 |
| Zamora, SA | 2 |
| Belli, DC | 3 |
| Friedli, B | 2 |
| Jaeggi, E | 1 |
| Craig, JS | 1 |
| Mikhail, A | 1 |
| Fischer, C | 1 |
| Patel, A | 1 |
| Long, MA | 1 |
| Limberis, JT | 2 |
| Martin, RL | 1 |
| Cox, BF | 2 |
| Gintant, GA | 2 |
| Su, Z | 1 |
| Danielsson, BR | 1 |
| Danielsson, C | 1 |
| Nilsson, MF | 1 |
| Darpö, B | 2 |
| Toga, T | 1 |
| Kohmura, Y | 1 |
| Kawatsu, R | 1 |
| Pettignano, R | 1 |
| Chambliss, CR | 1 |
| Darsey, E | 1 |
| Heard, M | 1 |
| Clark, R | 1 |
| Puisieux, FL | 1 |
| Adamantidis, MM | 1 |
| Dumotier, BM | 1 |
| Dupuis, BA | 1 |
| Jenkins, IR | 1 |
| Chan-Tompkins, NH | 1 |
| Babinchak, TJ | 1 |
| Carlsson, L | 1 |
| Amos, GJ | 1 |
| Andersson, B | 1 |
| Drews, L | 1 |
| Wadstedt, G | 1 |
| Doig, JC | 1 |
| Levine, A | 1 |
| Fogelman, R | 1 |
| Sirota, L | 1 |
| Zangen, Z | 1 |
| Shamir, R | 1 |
| Dinari, G | 1 |
| Mariscal, E | 1 |
| Sagalés, M | 1 |
| Pedrol, E | 2 |
| Montull, S | 1 |
| Telò, D | 1 |
| Vandenplas, Y | 2 |
| Benatar, A | 2 |
| Cadranel, S | 1 |
| Cucchiara, S | 1 |
| Dupont, C | 1 |
| Gottrand, F | 1 |
| Hassall, E | 1 |
| Heymans, HS | 1 |
| Kearns, G | 2 |
| Kneepkens, CM | 1 |
| Koletzko, S | 1 |
| Milla, P | 1 |
| Polanco, I | 1 |
| Staiano, AM | 1 |
| Shulman, RJ | 1 |
| Boyle, JT | 1 |
| Colletti, RB | 1 |
| Friedman, RA | 1 |
| Heyman, MB | 1 |
| Kirschner, BS | 1 |
| Levy, J | 2 |
| Mitchell, AA | 1 |
| Van Hare, G | 1 |
| Szneke, P | 1 |
| Weatherby, LB | 1 |
| Dicker, LW | 1 |
| Lanza, LL | 1 |
| Loughlin, JE | 1 |
| Yee, CL | 1 |
| Dreyer, NA | 1 |
| Evans, JS | 1 |
| Huffman, S | 1 |
| Dubin, AM | 1 |
| Van Hare, GF | 1 |
| Miller, JL | 1 |
| Gordon, D | 1 |
| Pelov, R | 1 |
| Tankova, L | 1 |
| Krushkov, I | 1 |
| Greene, HL | 1 |
| Napolitano, C | 1 |
| Schwartz, PJ | 1 |
| Ronchetti, E | 1 |
| Bianchi, L | 1 |
| Pinnavaia, A | 1 |
| Acquaro, G | 1 |
| Priori, SG | 1 |
| Richter, JE | 1 |
| Tutar, HE | 1 |
| Kansu, A | 1 |
| Kalayci, AG | 1 |
| Girgin, N | 1 |
| Atalay, S | 1 |
| Imamoğlu, A | 1 |
| Massari, FM | 1 |
| Trevano, FQ | 1 |
| Diehl, L | 1 |
| Romano, S | 1 |
| Drolet, B | 1 |
| Rousseau, G | 1 |
| Daleau, P | 1 |
| Cardinal, R | 1 |
| Turgeon, J | 1 |
| Griffin, JP | 1 |
| Ramírez-Mayans, J | 1 |
| Garrido-García, LM | 1 |
| Huerta-Tecanhuey, A | 1 |
| Gutierrez-Castrellón, P | 1 |
| Cervantes-Bustamante, R | 1 |
| Mata-Rivera, N | 1 |
| Zárate-Mondragón, F | 1 |
| Hentges, MJ | 1 |
| Gunderson, BW | 1 |
| Lewis, MJ | 1 |
| Feenstra, A | 1 |
| Decraene, T | 1 |
| Morawiecka, I | 1 |
| Sunil, S | 1 |
| Sinha, S | 1 |
| Cheetham, M | 1 |
| McDermott, JS | 1 |
| Wegner, CD | 1 |
| Dubin, A | 1 |
| Kikkert, M | 1 |
| Mirmiran, M | 1 |
| Ariagno, R | 1 |
| Hayes, C | 1 |
| Kern, J | 1 |
| Harris, J | 1 |
| Flores, A | 1 |
| Hyams, J | 1 |
| Murray, R | 1 |
| Tolia, V | 1 |
| Wysowski, DK | 1 |
| Corken, A | 1 |
| Gallo-Torres, H | 1 |
| Talarico, L | 1 |
| Rodriguez, EM | 1 |
| Ferrazzini, G | 1 |
| Arnott, W | 1 |
| Potet, F | 1 |
| Bouyssou, T | 1 |
| Escande, D | 1 |
| Baró, I | 1 |
| Mathis, AS | 1 |
| Costeas, C | 1 |
| Barone, JA | 1 |
| Rana, S | 1 |
| Sharma, B | 1 |
| Sugiyam, A | 1 |
| Ishida, Y | 1 |
| Satoh, Y | 1 |
| Aoki, S | 1 |
| Hori, M | 1 |
| Akie, Y | 1 |
| Kobayashi, Y | 1 |
| Hashimoto, K | 1 |
| Paakkari, I | 1 |
| Barbey, JT | 1 |
| Lazzara, R | 1 |
| Zipes, DP | 1 |
| Kuroda, T | 1 |
| Yoshihara, Y | 1 |
| Nakamura, H | 1 |
| Azumi, T | 1 |
| Inatome, T | 1 |
| Fukuzaki, H | 1 |
| Takanashi, H | 1 |
| Yogo, K | 1 |
| Akima, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Caffeine Ingestion in Prevention of Postoperative Ileus After Caesarean Section: A Randomized Controlled Trial[NCT03815877] | 600 participants (Actual) | Interventional | 2018-01-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for cisapride and Arrhythmias, Cardiac
| Article | Year |
|---|---|
[Proarrhythmic effects of domperidone in infants: a systematic review].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Cisapride; Contraindications; Cytochrome P-450 CYP3A; Dom | 2014 |
Cisapride for intestinal constipation.
Topics: Adult; Arrhythmias, Cardiac; Child; Cisapride; Constipation; Female; Gastrointestinal Agents; Humans | 2011 |
Embryonic cardiac arrhythmia and generation of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmias, Cardiac; | 2007 |
Detection and reporting of drug-induced proarrhythmias: room for improvement.
Topics: Adverse Drug Reaction Reporting Systems; Arrhythmias, Cardiac; Cisapride; Drug Labeling; Gastrointes | 2007 |
Drug-induced cardiac arrhythmias: incidence, prevention and management.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-Infective Agents; | 1997 |
[Severe proarrhythmias in cisapride therapy. Simple precautionary measures reduce the risk].
Topics: Anti-Ulcer Agents; Arrhythmias, Cardiac; Cisapride; Humans; Long QT Syndrome; Piperidines; Risk Fact | 1997 |
The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
Topics: Arrhythmias, Cardiac; Cisapride; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Intera | 1999 |
The use of cisapride in children. The North American Society for Pediatric Gastroenterology and Nutrition.
Topics: Arrhythmias, Cardiac; Aryl Hydrocarbon Hydroxylases; Cisapride; Cytochrome P-450 CYP3A; Cytochrome P | 1999 |
Update on medications used to treat gastrointestinal disease in children.
Topics: Anti-Bacterial Agents; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Child; Cisapride; Dru | 1999 |
Advances in the treatment of cardiac rhythm disturbances.
Topics: Adrenergic alpha-Agonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Electrophysiolog | 1999 |
[The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe?].
Topics: Arrhythmias, Cardiac; Cisapride; Drug Interactions; Electrocardiography; Gastrointestinal Agents; Hi | 1999 |
Cisapride: limited access and alternatives.
Topics: Anti-Ulcer Agents; Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Dyspepsia; Female; Ga | 2000 |
Cardiotoxicity of new antihistamines and cisapride.
Topics: Arrhythmias, Cardiac; Astemizole; Benzimidazoles; Butyrophenones; Cetirizine; Cisapride; Heart Disea | 2002 |
Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride.
Topics: Arrhythmias, Cardiac; Cisapride; Death, Sudden, Cardiac; Gastrointestinal Agents; Humans; Long QT Sy | 2002 |
5 trials available for cisapride and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Thorough QT/QTc Study Shows That a Novel 5-HT
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Arrhythmias, Cardiac; Asian People; Benzamides; | 2020 |
Cisapride and QTc interval in children.
Topics: Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Cisapride; Electrocardiography, Ambulator | 2000 |
Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography.
Topics: Arrhythmias, Cardiac; Cisapride; Electrocardiography; Gastroesophageal Reflux; Gastrointestinal Agen | 2000 |
Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study.
Topics: Arrhythmias, Cardiac; Child, Preschool; Cisapride; Electrocardiography; Female; Gastroesophageal Ref | 2001 |
Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants.
Topics: Arrhythmias, Cardiac; Biomarkers; Cisapride; Electrocardiography; Electrophysiology; Gastroesophagea | 2001 |
51 other studies available for cisapride and Arrhythmias, Cardiac
| Article | Year |
|---|---|
A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Topics: Arrhythmias, Cardiac; Cation Transport Proteins; Cell Line; Cisapride; DNA-Binding Proteins; Electro | 1997 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms.
Topics: Action Potentials; Arrhythmias, Cardiac; Cardiotoxicity; Cisapride; Drug Evaluation, Preclinical; HE | 2022 |
Cardiovascular effects of cisapride and prucalopride on human 5-HT
Topics: Animals; Arrhythmias, Cardiac; Atrial Function; Benzofurans; Cardiotonic Agents; Cisapride; Heart Ra | 2018 |
Temperature Effects on Kinetics of KV11.1 Drug Block Have Important Consequences for In Silico Proarrhythmic Risk Prediction.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; CHO Cells; Cisapride; Computer Simulation; Criceti | 2016 |
Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes.
Topics: Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Case-Control Studies; Cisapride; Dr | 2017 |
Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database.
Topics: Arrhythmias, Cardiac; Cisapride; Cohort Studies; Databases, Factual; Death, Sudden, Cardiac; Domperi | 2008 |
Cisapride and ventricular arrhythmia.
Topics: Adult; Aged; Arrhythmias, Cardiac; Case-Control Studies; Cisapride; Cytochrome P-450 CYP3A; Death, S | 2008 |
[Cardiac safety of cinitapride].
Topics: Arrhythmias, Cardiac; Aryl Hydrocarbon Hydroxylases; Benzamides; Cisapride; Cytochrome P-450 CYP2C8; | 2010 |
Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2012 |
Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts.
Topics: Animals; Arrhythmias, Cardiac; Cisapride; Electrocardiography; Feasibility Studies; Glucose; Heart; | 2012 |
Impact of amiodarone and cisapride on simulated human ventricular electrophysiology and electrocardiograms.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Computer Simulation; Drug Thera | 2012 |
Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Arrhythmias, Cardiac; Child; Child, Preschool; Cis | 2002 |
QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Consciousness; Electro | 2003 |
24-hour electrocardiogram before and during cisapride treatment in neonates and infants.
Topics: Arrhythmias, Cardiac; Bradycardia; Cisapride; Electrocardiography; Gastroesophageal Reflux; Gestatio | 2004 |
Cisapride and intestinal dysmotility: the final word?
Topics: Arrhythmias, Cardiac; Cisapride; Digestive System Diseases; Gastrointestinal Agents; Gastrointestina | 2005 |
Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; beta-Cyclodextrins; | 2007 |
The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities.
Topics: Aminopyridines; Arrhythmias, Cardiac; Benzamides; Cell Line; Cisapride; Electrophysiology; Ether-A-G | 2007 |
Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support.
Topics: Arrhythmias, Cardiac; Child; Cisapride; Extracorporeal Circulation; Female; Gastrointestinal Motilit | 1996 |
Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cisapride; Electrophysiolo | 1996 |
Cisapride in reducing postoperative gastrocaecal transit time after cardiac surgery in children.
Topics: Arrhythmias, Cardiac; Cardiac Surgical Procedures; Child; Cisapride; Gastrointestinal Agents; Gastro | 1997 |
Cardiac arrhythmias associated with coadministration of azole compounds and cisapride.
Topics: Antifungal Agents; Arrhythmias, Cardiac; Cisapride; Drug Interactions; Humans; Ketoconazole; Piperid | 1997 |
Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Benzamides; Cisapride; Guinea Pigs; Heart; In Vitr | 1997 |
QT interval in children and infants receiving cisapride.
Topics: Arrhythmias, Cardiac; Child; Cisapride; Electrocardiography; Gastrointestinal Agents; Gastrointestin | 1998 |
[Extrapyramidalism associated with the use of cisapride].
Topics: Aged; Anti-Ulcer Agents; Arrhythmias, Cardiac; Cisapride; Humans; Male; Nervous System Diseases; Par | 1998 |
[The arrhythmogenic potentials of cisapride].
Topics: Arrhythmias, Cardiac; Cisapride; Gastrointestinal Agents; Humans | 1998 |
The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anti-Ulcer Agents; Arrhythmias, Cardia | 1999 |
FDA, Janssen bolster cardiac risk warnings for cisapride.
Topics: Anti-Ulcer Agents; Arrhythmias, Cardiac; Cisapride; Drug Labeling; Humans; United States; United Sta | 2000 |
New safety recommendations for use of cisapride (Propulsid).
Topics: Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Gastroesophageal Reflux; Gastrointestina | 2000 |
Cisapride to be taken off market, placed in controlled-access plan.
Topics: Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Humans; United States; United States Foo | 2000 |
Reduced access to gastric motility drug will not sit well with many physicians or patients.
Topics: Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Gastrointestinal Agents; Humans | 2000 |
Drug recalls underscore safety concerns.
Topics: Arrhythmias, Cardiac; Chromans; Cisapride; Drug and Narcotic Control; Gastrointestinal Agents; Human | 2000 |
Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Cisapride; Critical Illness; Female; Gastrointestinal Agents; Humans; KC | 2000 |
Effects of cisapride on ventricular repolarization in children.
Topics: Action Potentials; Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Cisapride; Cyto | 2000 |
[Long QT interval and malignant ventricular arrhythmia during treatment with cisapride. Report of a clinical case].
Topics: Aged; Arrhythmias, Cardiac; Cisapride; Electrocardiography; Gastrointestinal Agents; Heart Ventricle | 2000 |
Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders.
Topics: Action Potentials; Animals; Antiemetics; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cation Tr | 2000 |
Prepulsid withdrawn from UK & US markets.
Topics: Adverse Drug Reaction Reporting Systems; Arrhythmias, Cardiac; Child, Preschool; Cisapride; Drug and | 2000 |
Retrospective analysis of cisapride-induced QT changes in end-stage renal disease patients.
Topics: Arrhythmias, Cardiac; Cisapride; Diabetic Nephropathies; Electrocardiography; Ethnicity; Female; Gas | 2000 |
Cisapride (Prepulsid): interactions with grapefruit and drugs.
Topics: Anti-Ulcer Agents; Arrhythmias, Cardiac; Aryl Hydrocarbon Hydroxylases; Beverages; Cisapride; Citrus | 2000 |
Postoperative ileus: a preventable event (Br J Surg 2000; 87: 1480-93).
Topics: Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Gastrointestinal Agents; Humans; Intesti | 2001 |
Postoperative ileus: a preventable event (Br J Surg 2000; 87: 1480-93).
Topics: Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Gastrointestinal Agents; Humans; Intesti | 2001 |
The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Topics: Action Potentials; Animals; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Cisapride; D | 2001 |
Cisapride associated with QTc prolongation in very low birth weight preterm infants.
Topics: Arrhythmias, Cardiac; Cisapride; Dose-Response Relationship, Drug; Drug and Narcotic Control; Electr | 2001 |
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
Topics: Adverse Drug Reaction Reporting Systems; Arrhythmias, Cardiac; Cisapride; Contraindications; Drug an | 2001 |
Cisapride and the Vanessa Young inquest.
Topics: Arrhythmias, Cardiac; Bulimia; Cause of Death; Cisapride; Contraindications; Female; Gastrointestina | 2001 |
Severe cardiac arrythmia on cisapride.
Topics: Adult; Arrhythmias, Cardiac; Canada; Child, Preschool; Cisapride; Drug and Narcotic Control; Drug In | 2000 |
Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel.
Topics: Animals; Arrhythmias, Cardiac; Benzamides; Benzofurans; Bridged Bicyclo Compounds, Heterocyclic; Cat | 2001 |
Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients.
Topics: Arrhythmias, Cardiac; Cisapride; Contraindications; Drug Interactions; Electrocardiography; Female; | 2001 |
Cisapride--a word of caution.
Topics: Arrhythmias, Cardiac; Canada; Cisapride; Electrocardiography; Gastroesophageal Reflux; Humans; Risk | 2001 |
Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs.
Topics: Animals; Arrhythmias, Cardiac; Atrioventricular Node; Blood Pressure; Body Weight; Cisapride; Dogs; | 2002 |
Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide.
Topics: Administration, Oral; Animals; Arrhythmias, Cardiac; Cisapride; Disopyramide; Dogs; Drug Synergism; | 1992 |